HCL Technologies ingår partnerskap med Oracle Health Sciences
Stockholm, 6 augusti, 2019: – Det globala teknologiföretaget HCL Technologies (HCL) och Oracle Health Sciences har ingått ett partnerskap som syftar till att hjälpa företag inom sjuk- och hälsovårdsbranschen att snabbt och effektivt kunna ta till sig, och skala upp användningen av, nästa generations digitala lösningar för kliniska studier. Därigenom ska företagen kunna minska tiden och kostnaderna för utveckling av nya läkemedel. Samarbetet omfattar HCL:s lösning Faster Intelligent Trials (FIT) i kombination med Oracle Health Sciences Mobile Health (mHealth) Connector Cloud Service (Oracle mHealth Cloud).
HCL:s lösning kan användas för flera use cases, inklusive patientsamverkan, sammanställning av inrapporterade patientresultat, hantering av patientsäkerhet och elektroniska möten under kliniska studier. Lösningen kan också appliceras på läkemedel som redan lanserats på marknaden, exempelvis genom en lösning för elektronisk övervakning av patienter, insamling av realtidsinformation eller som en kompletterande applikation för digital vård.
Shrikanth Shetty, Executive Vice President och North America Business Head för Life Sciences och Healthcare på HCL, säger:
- Trots att många av våra kunder redan har etablerat en solid grund för att använda mHealth-teknologier i kliniska studier eller vid digitalt baserad vård, ser vi fortfarande en klyfta mellan potentialen som finns och hur lösningarna används i verkligheten. Som en strategisk partner till flera stora företag i branschen, erbjuder HCL heltäckande tjänster som hjälper företag att gå från konceptutveckling till kliniska studier och efterföljande steg.
- Hälso- och sjukvårdssektorn har stora möjligheter att förändra sättet att samverka med patienter under kliniska studier. Samarbetet mellan Oracle Health Sciences och HCL gör det möjligt att skapa digitala processer och metoder. Detta är en intressant tid för läkemedelsindustrin tack vare att nya teknologier som mHealth fortsätter att effektivisera och snabba på kliniska studier, säger Jim Streeter, Global Vice President, Product Strategy, för Oracle Health Sciences.
HCL:s och Oracles gemensamma erbjudande inom mHealth ska hjälpa kunder över flera utvecklingsstadier. De som vill kan även välja att pröva konceptet under period på 6-8 veckor. Företag som kommit långt inom mHealth kan använda HCL FIT med Oracle mHealth Cloud “as a service” för specifika kliniska studier. HCL erbjuder även implementeringstjänster för företag som vill införa Oracle mHealth Cloud som företagsplattform för alla sina mHealth-initiativ.
HCL har erfarenhet av att stödja cirka 50 000 kliniska studier på 172 000 ställen över hela världen.
About Oracle
The Oracle Cloud offers complete SaaS application suites for ERP, HCM and CX, plus best-in-class database Platform as a Service (PaaS) and Infrastructure as a Service (IaaS) from data centers throughout the Americas, Europe and Asia. For more information about Oracle (NYSE:ORCL), please visit us at oracle.com
About Oracle Health Sciences
Oracle Health Sciences breaks down barriers and opens new pathways to unify people and processes to bring new drugs to market faster. As a number one provider of eClinical solutions (Everest Group, 2017) and powered by the number one data management technology in the world (Gartner, 2018), Oracle Health Sciences technology is trusted by 20 of the top 30 pharma, 10 of the top 10 biotech and 10 of the top 10 CROs for clinical trial and safety management around the globe.
About Oracle Health Sciences mHealth Connector Cloud Service
Oracle Health Sciences mHealth Connector Cloud Service monitors, aggregates and distributes data from mHealth devices/sources including wearables, sensors and apps and integrates that data into Oracle Health Sciences Clinical One eClinical platform, and other clinical systems.
Oracle Health Sciences Connect
For more information about how Oracle is committed to empowering organizations through best-in-class, industry-specific business solutions, visit oracle.com/industries. To learn more about Oracle Health Sciences Connect 2019, go to oracle.com/health-sciences-connect.
About HCL Technologies
HCL Technologies (HCL) is a leading global technology company that helps global enterprises re–imagine and transform their businesses through Digital technology transformation. HCL operates out of 44 countries and has consolidated revenues of US$ 8.6 billion, for financial year ended 31st March, 2019. HCL focuses on providing an integrated portfolio of services underlined by its Mode 1–2–3 growth strategy. Mode 1 encompasses the core services in the areas of Applications, Infrastructure, BPO and Engineering & R&D services, leveraging DRYiCE™ Autonomics to transform clients' business and IT landscape, making them 'lean' and 'agile'. Mode 2 focuses on experience–centric and outcome–oriented integrated offerings of Digital & Analytics, IoT WoRKS™, Cloud Native Services and Cybersecurity & GRC services to drive business outcomes and enable enterprise digitalization. Mode 3 strategy is ecosystem–driven, creating innovative IP–partnerships to build products and platforms business. HCL leverages its global network of integrated co-innovation labs and global delivery capabilities to provide holistic multi–service delivery in key industry verticals including Financial Services, Manufacturing, Telecommunications, Media, Publishing, Entertainment, Retail & CPG, Life Sciences & Healthcare, Oil & Gas, Energy & Utilities, Travel, Transportation & Logistics and Government. With 137,965 professionals from diverse nationalities, HCL focuses on creating real value for customers by taking 'Relationships Beyond the Contract'. For more information, please visit www.hcltech.com
Forward–looking Statements
Certain statements in this release are forward-looking statements, which involve a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from those in such forward-looking statements. All statements, other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to the statements containing the words 'planned', 'expects', 'believes’,’ strategy', 'opportunity', 'anticipates', 'hopes' or other similar words. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding impact of pending regulatory proceedings, fluctuations in earnings, our ability to manage growth, intense competition in IT services, business process outsourcing and consulting services including those factors which may affect our cost advantage, wage increases in India, customer acceptances of our services, products and fee structures, our ability to attract and retain highly skilled professionals, our ability to integrate acquired assets in a cost-effective and timely manner, time and cost overruns on fixed-price, fixed-timeframe contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, the success of our brand development efforts, liability for damages on our service contracts, the success of the companies /entities in which we have made strategic investments, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property, other risks, uncertainties and general economic conditions affecting our industry. There can be no assurance that the forward-looking statements made herein will prove to be accurate, and issuance of such forward-looking statements should not be regarded as a representation by the Company, or any other person, that the objective and plans of the Company will be achieved. All forward-looking statements made herein are based on information presently available to the Management of the Company and the Company does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the Company.
For further details please contact:
HCL Technologies
Anne Coyle
Elka Ghudial, Europe
Devneeta Pahuja, India and APAC
Trademark
Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.